Ranbaxy reports significant first-quarter growth

Ranbaxy has announced its financial results for the first quarter of 2012, during which it generated a consolidated sales total of $736 million (458 million pounds).

This represented a significant increase of around 55 percent from the corresponding period of last year, with profit and earnings also seeing double-digit increases.

The company's major operations – including its north American, western European, Asia Pacific and active pharmaceutical ingredients businesses – all experienced growth, while major products such as Atorvastatin and Ran-Rosuvastatin were successfully launched.

Other key developments included the resumption of exports to the USA from Ranbaxy's Indian facility, while efforts to improve efficiency also progressed well.

Arun Sawhney, chief executive officer and managing director at the firm, said: "The company is working towards creating a sustainable, profitable, growing business in the long run with differentiated, branded generics business at its base."

This comes after the company posted record-breaking annual sales of $2.11 billion last year.